Guidelines for the safe administration of high-dose interleukin-2.
作者： Douglas J. Schwartzentruber
DOI: 10.1097/00002371-200107000-00004
关键词:
摘要: High-dose interleukin-2 (IL-2) results in objective clinical regression of metastatic cancer 15% to 17% patients with melanoma and renal cell carcinoma. Durable complete all metastases is seen 6% 8% patients. Based on these findings, the U.S. Food Drug Administration has approved use high-dose IL-2 for treatment Interleukin-2 administration associated many different side effects, after years use, clinicians have learned how safely administer IL-2. This article details practical guidelines safe
lww.com 
isocenter.org 
researchgate.net 参考文章(14)
Steven A. Rosenberg, Gwendolyn Fyfe, Gwendolyn Fyfe, Richard I. Fisher, Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. The cancer journal from Scientific American. ,vol. 6, ,(2000)
B A Pockaj, S L Topalian, S M Steinberg, D E White, S A Rosenberg, Infectious complications associated with interleukin-2 administration: a retrospective review of 935 treatment courses. Journal of Clinical Oncology. ,vol. 11, pp. 136- 147 ,(1993) , 10.1200/JCO.1993.11.1.136
Mark P. Macfarlane, James C. Yang, Anshu S. Guleria, Richard L White, Claudia A. Seipp, Jan H. Einhorn, Donald E. White, Steven A. Rosenberg, The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell carcinoma Cancer. ,vol. 75, pp. 1030- 1037 ,(1995) , 10.1002/1097-0142(19950215)75:4<1030::AID-CNCR2820750420>3.0.CO;2-5
Steven A. Rosenberg, James C. Yang, Donald E. White, Seth M. Steinberg, Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Annals of Surgery. ,vol. 228, pp. 307- 319 ,(1998) , 10.1097/00000658-199809000-00004
Hyun Kim, Steven A. Rosenberg, Seth M. Steinberg, David J. Cole, Jeffrey S. Weber, A randomized double-blinded comparison of the antiemetic efficacy of ondansetron and droperidol in patients receiving high-dose interleukin-2. Journal of Immunotherapy. ,vol. 16, pp. 60- 65 ,(1994) , 10.1097/00002371-199407000-00006
Richard L. White, Douglas J. Schwartzentruber, Anshu Guleria, Mark P. Macfarlane, Donald E. White, Eben Tucker, Steven A. Rosenberg, Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma. Cancer. ,vol. 74, pp. 3212- 3222 ,(1994) , 10.1002/1097-0142(19941215)74:12<3212::AID-CNCR2820741221>3.0.CO;2-I
Robert S. Krouse, Richard E. Royal, Glenroy Heywood, Bruce D. Weintraub, Donald E. White, Seth M. Steinberg, Steven A. Rosenberg, Douglas J. Schwartzentruber, Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone. Journal of Immunotherapy. ,vol. 18, pp. 272- 278 ,(1995) , 10.1097/00002371-199511000-00008
KIRK D DENICOFF, DAVID R RUBINOW, MOSHE Z PAPA, COLLEEN SIMPSON, CLAUDIA A SEIPP, MICHAEL T LOTZE, ALFRED E CHANG, DONALD ROSENSTEIN, STEVEN A ROSENBERG, The Neuropsychiatric Effects of Treatment with Interleukin-2 and Lymphokine-Activated Killer Cells Annals of Internal Medicine. ,vol. 107, pp. 293- 300 ,(1987) , 10.7326/0003-4819-107-2-293
Udai S. Kammula, Donald E. White, Steven A. Rosenberg, Trends in the safety of high dose bolus interleukin‐2 administration in patients with metastatic cancer Cancer. ,vol. 83, pp. 797- 805 ,(1998) , 10.1002/(SICI)1097-0142(19980815)83:4<797::AID-CNCR25>3.0.CO;2-M
Barbara A. Pockaj, James C. Yang, Michael T. Lotze, Julie R. Lange, William F. Spencer, Seth M. Steinberg, Suzanne L. Topalian, Douglas J. Schwartzentruber, Donald E. White, Steven A. Rosenberg, A prospective randomized trial evaluating colloid versus crystalloid resuscitation in the treatment of the vascular leak syndrome associated with interleukin-2 therapy. Journal of Immunotherapy. ,vol. 15, pp. 22- 28 ,(1994) , 10.1097/00002371-199401000-00003